Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Atrial Fibrillation | Original investigation

Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study

Authors: Shilan Seyed Ahmadi, Ann-Marie Svensson, Aldina Pivodic, Annika Rosengren, Marcus Lind

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

To examine the incidence of atrial fibrillation in individuals with type 2 diabetes compared with age- and sex-matched controls from the general population and its variation in relation to glycaemic control and renal function.

Methods

A total of 421,855 patients with type 2 diabetes from the Swedish National Diabetes Registry and 2,131,223 controls from the Swedish Population Registry, matched for age, sex and county, were included and followed from January 1, 2001 to December 31, 2013.

Results

Overall, 8.9% of individuals with type 2 diabetes and 7.0% of controls were diagnosed with atrial fibrillation during follow-up, unadjusted incidence risk ratio (IRR) 1.35 (95% 1.33–1.36). Women < 55 years old with type 2 diabetes had an IRR of 2.36 (95% CI 2.10–2.66), in relation to controls, whereas the corresponding value for men < 55 years old with type 2 diabetes was IRR 1.78 (95% CI 1.67–1.90). In the fully adjusted Cox regression, the risk of type 2 diabetes on incident atrial fibrillation was 28% greater vs controls, hazard ratio (HR) 1.28 (95% CI 1.26–1.30), p < 0.0001. The excess risk of atrial fibrillation in individuals with type 2 diabetes increased with worsening glycaemic control and renal complications. For individuals with HbA1c ≤ 6.9% (≤ 52 mmol/mol) and normoalbuminuria the excess risk vs controls was still increased, adjusted HR 1.16 (95% CI 1.14–1.19); p < 0.0001.

Conclusions

Individuals with type 2 diabetes had an overall 35% higher risk of atrial fibrillation compared to age- and sex-matched controls from the general population. The excess risk for atrial fibrillation increased with renal complications or with poor glycaemic control. Individuals with type 2 diabetes with good glycaemic control and normoalbuminuria had slightly increased risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabet. 2015;6(4):598–612.CrossRef Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabet. 2015;6(4):598–612.CrossRef
2.
go back to reference Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–20.CrossRef Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–20.CrossRef
3.
go back to reference Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017;14:88.CrossRef Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017;14:88.CrossRef
4.
go back to reference Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non-vitamin k antagonist oral anticoagulants: a review. JAMA Cardiol. 2017;2(4):442–8.CrossRef Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non-vitamin k antagonist oral anticoagulants: a review. JAMA Cardiol. 2017;2(4):442–8.CrossRef
5.
go back to reference Movahed M-R, Hashemzadeh M, Mazen Jamal M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105(3):315–8.CrossRef Movahed M-R, Hashemzadeh M, Mazen Jamal M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105(3):315–8.CrossRef
6.
go back to reference Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2001;250(5):382–9.CrossRef Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2001;250(5):382–9.CrossRef
7.
go back to reference Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. Framingham Heart Study JAMA. 1994;271(11):840–4.PubMed Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. Framingham Heart Study JAMA. 1994;271(11):840–4.PubMed
8.
go back to reference Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the atherosclerosis risk in communities study. Heart. 2012;98(2):133–8.CrossRef Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the atherosclerosis risk in communities study. Heart. 2012;98(2):133–8.CrossRef
9.
go back to reference Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Svensson A-M, Cederholm J. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia. 2015;58(10):2259–68.CrossRef Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Svensson A-M, Cederholm J. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia. 2015;58(10):2259–68.CrossRef
10.
go back to reference Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabet Complicat. 2018;32(5):501–11.CrossRef Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabet Complicat. 2018;32(5):501–11.CrossRef
11.
go back to reference Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.CrossRef Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.CrossRef
12.
go back to reference Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.CrossRef Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.CrossRef
13.
go back to reference Dahlqvist S, Rosengren A, Gudbjornsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabet Endocrinol. 2017;5(10):799–807.CrossRef Dahlqvist S, Rosengren A, Gudbjornsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabet Endocrinol. 2017;5(10):799–807.CrossRef
14.
go back to reference Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56–62.CrossRef Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56–62.CrossRef
15.
go back to reference Pallisgaard JL, Schjerning AM, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621–7.CrossRef Pallisgaard JL, Schjerning AM, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621–7.CrossRef
16.
go back to reference Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol. 2012;60(15):1421–8.CrossRef Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol. 2012;60(15):1421–8.CrossRef
17.
go back to reference Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabet Obes Metab. 2004;6(5):367–74.CrossRef Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabet Obes Metab. 2004;6(5):367–74.CrossRef
18.
go back to reference Miyake H, Kanazawa I, Sugimoto T. Albuminuria Increases all-cause mortality in japanese patients with type 2 diabetes mellitus. J Clin Med. 2018;7(9):234.CrossRef Miyake H, Kanazawa I, Sugimoto T. Albuminuria Increases all-cause mortality in japanese patients with type 2 diabetes mellitus. J Clin Med. 2018;7(9):234.CrossRef
19.
go back to reference Anyanwagu U, Donnelly R, Idris I. Albuminuria regression and all-cause mortality among insulin-treated patients with type 2 diabetes: analysis of a large UK primary care cohort. Am J Nephrol. 2019;49(2):146–55.CrossRef Anyanwagu U, Donnelly R, Idris I. Albuminuria regression and all-cause mortality among insulin-treated patients with type 2 diabetes: analysis of a large UK primary care cohort. Am J Nephrol. 2019;49(2):146–55.CrossRef
20.
go back to reference Rosengren A, Edqvist J, Rawshani A, Sattar N, Franzen S, Adiels M, et al. Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia. 2018;61(11):2300–9.CrossRef Rosengren A, Edqvist J, Rawshani A, Sattar N, Franzen S, Adiels M, et al. Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia. 2018;61(11):2300–9.CrossRef
21.
go back to reference Tancredi M, Rosengren A, Svensson AM, Pivodic A, Gudbjornsdottir S, Wedel H, et al. Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Open Heart. 2019;6(2):e000967.CrossRef Tancredi M, Rosengren A, Svensson AM, Pivodic A, Gudbjornsdottir S, Wedel H, et al. Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Open Heart. 2019;6(2):e000967.CrossRef
22.
go back to reference Hedén Ståhl C, Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, et al. Long-term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population-based case-control study. Diabet Med. 2017;34(4):522–30.CrossRef Hedén Ståhl C, Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, et al. Long-term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population-based case-control study. Diabet Med. 2017;34(4):522–30.CrossRef
23.
go back to reference Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55(11):2946–53.CrossRef Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55(11):2946–53.CrossRef
24.
go back to reference Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114(8):1217–22.CrossRef Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114(8):1217–22.CrossRef
25.
go back to reference Harati H, Zanetti D, Rao A, Gustafsson S, Perez M, Ingelsson E, et al. No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation. Diabetologia. 2019;62(5):800–4.CrossRef Harati H, Zanetti D, Rao A, Gustafsson S, Perez M, Ingelsson E, et al. No evidence of a causal association of type 2 diabetes and glucose metabolism with atrial fibrillation. Diabetologia. 2019;62(5):800–4.CrossRef
26.
go back to reference Gu J, Fan YQ, Zhang JF, Wang CQ. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. Anatolian J Cardiol. 2017;18(6):410–6. Gu J, Fan YQ, Zhang JF, Wang CQ. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. Anatolian J Cardiol. 2017;18(6):410–6.
27.
go back to reference Akoum N, Zelnick LR, de Boer IH, Hirsch IB, Trence D, Henry C, et al. Rates of cardiac rhythm abnormalities in patients with CKD and diabetes. Clin J Am Soc Nephrol CJASN. 2019;14(4):549–56.CrossRef Akoum N, Zelnick LR, de Boer IH, Hirsch IB, Trence D, Henry C, et al. Rates of cardiac rhythm abnormalities in patients with CKD and diabetes. Clin J Am Soc Nephrol CJASN. 2019;14(4):549–56.CrossRef
28.
go back to reference Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21(2):210–7.CrossRef Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21(2):210–7.CrossRef
29.
go back to reference Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117(10):1255–60.CrossRef Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117(10):1255–60.CrossRef
30.
go back to reference Packer M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):121.CrossRef Packer M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):121.CrossRef
31.
go back to reference Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. Front Physiol. 2018;9:1669.CrossRef Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. Front Physiol. 2018;9:1669.CrossRef
32.
go back to reference Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):120.CrossRef Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):120.CrossRef
33.
go back to reference Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Archiv Cardiovasc Dis. 2015;108(4):269–76.CrossRef Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Archiv Cardiovasc Dis. 2015;108(4):269–76.CrossRef
34.
go back to reference Kim YG, Han KD, Choi JI, Boo KY, Kim DY, Oh SK, et al. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128.CrossRef Kim YG, Han KD, Choi JI, Boo KY, Kim DY, Oh SK, et al. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128.CrossRef
35.
go back to reference Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18(1):125.CrossRef Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18(1):125.CrossRef
Metadata
Title
Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study
Authors
Shilan Seyed Ahmadi
Ann-Marie Svensson
Aldina Pivodic
Annika Rosengren
Marcus Lind
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0983-1

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine